XTM Files 2024 Annual Financial Results
Article content
Article content
TORONTO — XTM Inc. ('XTM' or the 'Company') (QB: XTMIF / CSE: PAID / FSE: 7XT), a fintech innovator in automated tip calculations, instant payouts for employees and gig workers and earned wage access ('EWA') through its AnyDay™ platform, today announced it has filed its audited financial statements and management's discussion and analysis (MD&A) for the fiscal year ended December 31, 2024 (the 'Required Filings').
Article content
With the April 25, 2025 announcement of a signed agreement with Pateno Payments Inc. ('Pateno'), a subsidiary of Digital Commerce Group, and the resulting long-term partnership and support from Digital Commerce Bank and its subsidiaries, the Company is now well-positioned to scale rapidly, backed by strong financial support and a robust infrastructure.
Article content
2024 Financial and Operational Highlights
Article content
Revenue Growth: Revenue increased 34% year-over-year to $9.1 million, driven by continued demand for XTM's payment solutions, despite ongoing economic pressures.
Gross Dollar Value (GDV): The Company processed more than $800 million in payments to hospitality sector employees — a 21% increase — with 95% of the volume generated in Canada.
New Client Growth: XTM added 689 new business locations in 2024, bringing total onboarded locations to more than 3,500 as of year-end 2024.
Platform Engagement: Active users on XTM's Today platform increased by 40% compared to the prior year. An active user is defined as one making at least one transaction via the Today wallet within a 30-day period.
Operational Streamlining: The Company focused on operational efficiency, reducing overhead, eliminating redundancies, and investing in long-term sales partnerships to support scalable growth.
Article content
CAD $13M Credit Facility: On January 1, 2025, XTM signed a CAD $13 million Letter of Credit with Pateno Payments to support growth and cash neutrality, ahead of a planned uplisting to a senior exchange in the second half 2025.
Processing Agreement: On April 25, 2025, XTM signed a USD $3 million agreement with Pateno Payments for QRails processing operations. The transaction is expected to cut monthly operating costs by approximately 50%. XTM retains full ownership and management of its proprietary AnyDay™ EWA platform, including client relationships and technology integrations.
Denver Office Virtualized: In March 2025, XTM moved to a virtual work environment, divesting itself of significant office overhead expenses.
Article content
Filing Details
Article content
The audited consolidated financial statements and MD&A for the year ended December 31, 2024, are available on the Company's profile at www.sedarplus.ca.
Article content
About XTM Inc.
Article content
XTM Inc. is a global fintech innovator with offices in Toronto and Miami. Through its AnyDay™ platform XTM delivers instant pay and Earned Wage Access solutions to restaurants, hospitality, personal care, and staffing sectors. XTM supports some of North America's leading brands including Earls, Marriott Hotels, Maple Leaf Sports & Entertainment, Cactus Club, and Live Nation.
Article content
Forward-Looking Statements
Article content
This press release contains 'forward-looking information' and 'forward-looking statements' within the meaning of applicable Canadian securities laws. These statements involve known and unknown risks, uncertainties, and assumptions, and may include words such as 'expects,' 'intends,' 'anticipates,' 'plans,' 'believes,' and similar expressions. Actual results could differ materially from those projected due to various risks and factors beyond the Company's control.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Contact:
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Union says 'nothing scheduled' with Air Canada as strike by flight attendants halts operations
Social Sharing The union representing Air Canada flight attendants says no talks are scheduled with the airline as a strike that began early Saturday led to the airline suspending operations. The union and airline met late Friday night before 10,000 flight attendants walked off the job at 12:58 a.m. ET, Wesley Lesosky, president of the Air Canada component of the Canadian Union of Public Employees (CUPE), told a morning news conference. Lesosky said their last meeting was Friday night, but Air Canada offered "nothing of substance" to bring back to members. Asked when Canadians could expect to be back on flights, Lesosky said it's up to Air Canada, but that public pressure on the airline will make a "huge difference" in reaching a settlement. CBC News has reached out to Air Canada for comment and will update this story with any response. Jobs Minister Patty Hajdu also met with both the airline and union on Friday night. "It is unacceptable that such little progress has been made. Canadians are counting on both parties to put forward their best efforts," Hajdu said on social media platform X. Picket lines set up across Canada All Air Canada and Air Canada Rouge flights are suspended for now. Around 130,000 customers will be affected each day the strike continues, said the airline. Flights by Air Canada Express, which are operated by third-party airlines Jazz and PAL, are not affected. Cross Country Checkup is asking: How have you been affected by the Air Canada strike? What should be done about it? Leave your comment here and we may read it or call you back for our show on Sunday. "Air Canada deeply regrets the effect the strike is having on customers," it said in a brief statement early Saturday morning. CUPE has set up picket lines at airports across Canada, including in Montreal, Toronto, Calgary and Vancouver. Striking flight attendants also plan to picket at airports in Halifax, Ottawa and Winnipeg. In the meantime, passengers around the world are feeling the effects of the flight attendants' strike. Keelin Pringnitz and her family are from Ottawa and were returning from a European vacation, but were left stranded after flights were cancelled. "It was an end of my maternity leave kind of trip. We went to the Faroe Islands and Norway, travelling through Air Canada to London," Pringnitz said from London's Heathrow Airport. She noted there was an option for travellers to go the U.S. but she and others were told there wouldn't be any further assistance once they landed in the U.S. "It didn't go over well with the line. Nobody really seemed interested, everybody seemed a little bit amused almost at the suggestion, or exasperated, because it is a bit ridiculous to offer to take stranded passengers to a different country to strand them there." For customers due to travel soon whose flights are not yet cancelled, Air Canada said it will allow them to rebook their travel or obtain a credit for future travel. Sides at an impasse on pay Air Canada and CUPE have been in contract talks for about eight months, but have yet to reach a tentative deal. Both sides say they remain far apart on the issue of pay and the unpaid work flight attendants do when planes aren't in the air. WATCH | Thousands of Air Canada flight attendants walk off the job: Air Canada strike begins as flight attendants walk off the job 2 hours ago More than 10,000 Air Canada flight attendants went on strike early Saturday morning, after the airline and the union representing them failed to reach a deal ahead of the deadline. With a work stoppage now in effect, Air Canada estimates that 130,000 customers will be affected each day of a strike, a figure that includes 25,000 Canadian travellers who are abroad. The airline's latest offer included a 38 per cent increase in total compensation, including benefits and pensions over four years, that it said "would have made our flight attendants the best compensated in Canada." But the union pushed back, saying the proposed 8 per cent raise in the first year didn't go far enough because of inflation. Government intervention Air Canada previously asked Hajdu to intervene by ordering the parties to enter a binding arbitration process — a power granted to the minister through Sec. 107 of the Canada Labour Code. On Friday, Hajdu urged Air Canada and the union to get back to the negotiating table, suggesting she's not ready to intervene. The minister said the union has indicated many of its demands have been met, suggesting there is a path forward to a deal. WATCH | The impact of the flight attendants' strike on travellers: Air Canada flight attendants strike, setting stage for travel chaos 10 hours ago Canada's largest airline is now mostly grounded after a strike deadline passed for more than 10,000 Air Canada flight attendants. Hundreds of flights have been cancelled impacting over 100,000 travellers and leaving some stranded. Hajdu had asked the union to respond to the company's request. CUPE indicated Friday it opposed arbitration, instead maintaining its desire to solve the impasse through bargaining.
Globe and Mail
an hour ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
2 hours ago
- Globe and Mail
1 Reason to Buy Robinhood Markets (HOOD) Stock
Key Points Robinhood is attracting new customers at a rapid clip. Revenue grew 45% in Q2, yet Robinhood still offers a limited range of services compared to big brokers. As it continues to roll out new features, Robinhood could see an avalanche of asset growth. 10 stocks we like better than Robinhood Markets › Robinhood Markets (NASDAQ: HOOD) is breaking a new mold in the fintech market. The stock has rocketed 490% higher over the past year, sending its market cap toward $100 billion. While the stock might look overbought after such a steep rally, its customer assets are still very small compared to other leading financial service companies, which leaves plenty of room for the company (and stock) to grow in value over the long term. The more services Robinhood brings customers, the more it grows Robinhood's platform assets have increased from $89 billion in the second quarter of 2023 to $279 billion in Q2 2025. With fee-generating services like Robinhood Gold continuing to gain traction, revenue grew 45% year over year in the second quarter to $989 million. This is why the stock is still a buy at these highs. Robinhood is seeing this much growth while offering limited services compared to big brokers like Schwab. As it catches up, Robinhood could grow into a multitrillion-dollar financial services company. Robinhood's pace of new announcements has been remarkable. In the first quarter, it rolled out index options to all customers, and it followed that up in the second quarter with the launch of stock tokens in Europe, allowing those customers to trade over 200 U.S. stocks in the form of tokenized contracts on a blockchain. By the end of the third quarter, Robinhood plans to launch its new banking service too. These are just a few of the many announcements the company has made recently. As it continues to launch new trading products, including its Cortex AI -powered trading tool later this year, its platform assets will likely continue to grow. There are several products, including fixed-income securities, that Robinhood can eventually tap into to further support its growth. For perspective, Schwab has over $10 trillion in client assets. I wouldn't bet against Robinhood CEO Vlad Tenev's ability to grow Robinhood into one of country's largest brokerage services. The stock still offers tremendous long-term upside. Should you invest $1,000 in Robinhood Markets right now? Before you buy stock in Robinhood Markets, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Robinhood Markets wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Charles Schwab is an advertising partner of Motley Fool Money. John Ballard has positions in Robinhood Markets. The Motley Fool recommends Charles Schwab and recommends the following options: short September 2025 $92.50 calls on Charles Schwab. The Motley Fool has a disclosure policy.
